Outcomes following DLI in patients with haematological malignancies: Donor characteristics matter.

[1]  S. Montoto,et al.  The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies , 2019, Bone Marrow Transplantation.

[2]  D. Porter,et al.  Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  Yong-yong Ma,et al.  Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia. , 2017, Leukemia research.

[4]  S Mackinnon,et al.  Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants , 2017, Bone Marrow Transplantation.

[5]  J. Snowden,et al.  Lineage‐specific chimerism monitoring after allogeneic haematopoietic stem cell transplantation: do we really know what we are measuring? , 2017, British journal of haematology.

[6]  M. Solh,et al.  Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  L. Castagna,et al.  Donor lymphocyte infusion after allogeneic stem cell transplantation. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[8]  S. Crawford,et al.  Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[10]  M. MacMillan,et al.  Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. , 2015, Blood.

[11]  S. Davies,et al.  Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  J. Snowden,et al.  Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): Technical recommendations for the use of Short Tandem Repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Wo , 2015, British journal of haematology.

[13]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  B. Sandmaier,et al.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. , 2014, Blood.

[15]  A. Bashey,et al.  Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial , 2014, Bone Marrow Transplantation.

[16]  M. Bar,et al.  Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  G. Mufti,et al.  Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  N. Kröger,et al.  Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings , 2013, Leukemia.

[19]  R. Bouabdallah,et al.  Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. , 2013, Experimental hematology.

[20]  J. Scarisbrick,et al.  Diagnosis and management of acute graft‐versus‐host disease , 2012, British journal of haematology.

[21]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[22]  I. Kayani,et al.  Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Ljungman,et al.  Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  S. Mackinnon,et al.  T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Baird,et al.  Chronic graft-versus-host disease (GVHD) in children. , 2010, Pediatric clinics of North America.

[26]  D. Porter,et al.  Graft-versus-host disease after donor leukocyte infusions: presentation and management. , 2008, Best practice & research. Clinical haematology.

[27]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Blaise,et al.  Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. , 2007, Haematologica.

[29]  N. Russell,et al.  The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  P. Tsirigotis,et al.  Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  S. Riddell,et al.  Molecules and mechanisms of the graft-versus-leukaemia effect , 2004, Nature Reviews Cancer.

[32]  S. Mackinnon,et al.  Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. , 2004, Blood.

[33]  S. Mackinnon,et al.  Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. , 2003, Blood.

[34]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[35]  G. Morgan,et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. , 2000, Blood.

[36]  N. Russell,et al.  Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow , 1999, British journal of haematology.

[37]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[38]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[39]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[40]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.